Latham Gregory J, Jardine David S
Department of Anesthesiology and Pain Medicine, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA 98105, USA.
Paediatr Anaesth. 2013 Oct;23(10):952-6. doi: 10.1111/pan.12192. Epub 2013 May 16.
Oxymetazoline nasal spray is not FDA approved for use in children less than 6 years; however, its safety and efficacy are widely accepted, and it is in widespread use in children prior to procedures that may lead to epistaxis. We report a case of intraoperative oxymetazoline toxicity in a 4-year-old boy that led to a hypertensive crisis. While examining the possible causes for this problem, we became aware that the method of drug delivery led to an unanticipated overdose. The position in which the bottle is held causes pronounced variation in the quantity of oxymetazoline dispensed.
To examine the impact that bottle position has on the volume delivered, we measured the volume of oxymetazoline dispensed with the bottle in the upright and inverted position. We also measured the volume of a drop of oxymetazoline dispensed from the bottle. Because an additional source of oxymetazoline exposure is from packing the nares with surgical pledgets, we analyzed the volume of oxymetazoline absorbed by each pledget.
Squeezing the bottle in the upright position results in a fine spray of fluid that averaged 28.9 ± 6.8 μl and was largely independent of effort. This volume is nearly identical to the measured volume of a drop of oxymetazoline, which was 30 μl. However, squeezing the bottle in the inverted position resulted in a steady stream of fluid, and the volume administered was completely effort dependent. Multiple tests in the inverted position demonstrated an average volume of 1037 ± 527 μl, with a range of 473-2196 μl. Lastly, the volume of oxymetazoline absorbed by each surgical pledget was 1511 ± 184 μl.
Our testing indicates that bottle position during oxymetazoline administration can cause up to a 75-fold increase in intended drug administration.
羟甲唑啉滴鼻剂未获美国食品药品监督管理局(FDA)批准用于6岁以下儿童;然而,其安全性和有效性已被广泛认可,并且在可能导致鼻出血的手术前广泛用于儿童。我们报告了一例4岁男孩术中发生羟甲唑啉中毒导致高血压危象的病例。在研究该问题的可能原因时,我们意识到给药方法导致了意外的过量用药。握持药瓶的姿势会导致羟甲唑啉的给药量出现显著差异。
为了研究药瓶位置对给药量的影响,我们测量了药瓶直立和倒置时羟甲唑啉的给药量。我们还测量了从药瓶中挤出的一滴羟甲唑啉的体积。由于羟甲唑啉暴露的另一个来源是用手术棉球填塞鼻孔,我们分析了每个棉球吸收的羟甲唑啉体积。
将药瓶直立挤压会产生平均为28.9±6.8微升的细喷雾,且在很大程度上与用力无关。这个体积与测得的一滴羟甲唑啉的体积几乎相同,为30微升。然而,将药瓶倒置挤压会产生一股稳定的液体流,给药量完全取决于用力程度。在倒置位置进行的多次测试显示平均体积为1037±527微升,范围为473 - 2196微升。最后,每个手术棉球吸收的羟甲唑啉体积为1511±184微升。
我们的测试表明,使用羟甲唑啉时药瓶的位置可导致预期给药量增加多达75倍。